1272317-01-7

Basic information

• Product Name: 1-azido-2-bromo-4- chlorobenzene
• Synonyms: 1-azido-2-bromo-4- chlorobenzene
• CAS NO: 1272317-01-7
• Molecular Weight: 232.467
• Mol File: 1272317-01-7.mol
• Article Data: 9

Chemical Properties

• CAS DataBase Reference: 1-azido-2-bromo-4- chlorobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 1-azido-2-bromo-4- chlorobenzene(1272317-01-7)
• EPA Substance Registry System: 1-azido-2-bromo-4- chlorobenzene(1272317-01-7)

Safety Data

• Hazardous Substances Data: 1272317-01-7(Hazardous Substances Data)

Upstream product

• 106-47-8 4-chloro-aniline 
• 873-38-1 4-chloro-2-bromoaniline 
• 3296-05-7 1-azido-4-chlorobenzene 

Downstream Products

• 94-97-3 5-chlorobenzotriazole 

Relevant articles and documents

Iron-catalyzed bromination of aryl azides by N-bromosuccinimide: Efficient method for the synthesis of brominated aryl azides

An efficient and mild protocol for bromination of aryl azides with N-bromosuccinimide (NBS) under FeCl3 catalysis in 1,2-dichloroethane was developed. It is proved to be an efficient method for obtaining brominated aryl azides.

Furo-pyridone imidazole compound as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry. Specifically, the invention relates to a furo-pyridone imidazole compound as well as a preparation method and application thereof. The structure of the compound is shown as a general formula (I). The compounds or the stereoisomers, racemes, geometric isomers, tautomers, prodrugs, hydrates, solvates or pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used for treating or/and preventing related diseases mediated by the FXIa (Factor XIa for short).

Alkoxy pyridone compound as well as preparation method and application thereof

The invention belongs to the field of medicinal chemistry, specifically, the invention relates to a series of inhibitors of factor XIa (FXIa for short) with a novel structure as well as a preparationmethod and an application thereof. The structure is shown as the following general formula (I). These compounds or stereoisomers, racemates, geometric isomers, tautomers, prodrugs, hydrates, solvatesor pharmaceutically acceptable salts and pharmaceutical compositions thereof can be used to treat or/and prevent related diseases mediated by factor XIa (FXIa for short).